Rose McNulty

Myeloproliferative neoplasms–unclassifiable (MPN-U), show distinct genetic and clinical patterns that differentiate them from essential thrombocythemia.

Synovial sarcoma—a rare, aggressive soft tissue cancer—can present as a painless hand swelling that mimics a harmless lesion, underscoring the need for early recognition and improved diagnostic access in low-resource settings.

The FDA has expanded sotatercept's indications for pulmonary arterial hypertension, following data showing significant drops in hospitalization and mortality risks.

The real-world data support the long-term value of mepolizumab as an add-on maintenance therapy in severe asthma.

CD45 + C1q + CCR8+ cells were found to be a novel immune-cell subset associated with kidney disease severity and progression risk.

Serum biochemical fingerprints can stratify chronic lymphocytic leukemia (CLL) outcomes and uncover heterogeneity within molecularly defined low-risk disease.

Chronic spontaneous urticaria (CSU) and atopic disorders seem to share an immunological basis and may significantly benefit from type 2 inflammation–targeted therapies.

Treatment options for patients with small cell lung cancer (SCLC) who survive to a third line of therapy are insufficient, authors of a new study argue.

Glucagon-like peptide 1 receptor agonists improved disease activity, body weight, and cholesterol in patients with rheumatoid arthritis.

Artificial intelligence models may advance clinical trial design and enrollment to improve trial success and patient outcomes.

Elinzanetant offers a new hormone-free solution for managing menopause-related hot flashes, targeting the root cause of vasomotor symptoms.

Questions remain related to which patients with diffuse large B-cell lymphoma (DLBCL) benefit most from radiotherapy and at what dose.

Belantamab mafodotin provides a community-friendly BCMA-directed therapy option for relapsed/refractory myeloma, says Hearn Jay Cho, MD, PhD.

The FDA has approved belantamab mafodotin for third-line or later multiple myeloma based on DREAMM-7 trial data.

A study reveals promising results for combining enfortumab vedotin and pembrolizumab in treating recurrent head and neck cancer, showing a 39% response rate.

Patients with fatty liver disease are significantly more likely to develop kidney stones, a national study found.

Dana-Farber researchers have uncovered mutation pathways driving aggressive disease transformation.

LAG-3 expression appears to be significantly elevated in patients with small cell lung cancer (SCLC).

Digitized behavioral cough suppression therapy is a safe, highly effective, and accessible alternative to drugs for chronic cough, said Laurie Slovarp, PhD.

CT scans can play a role not just in diagnosing but also in monitoring non–cystic fibrosis bronchiectasis management, explained James D. Chalmers, MD.

IO Biotech's immune-modulatory cancer vaccine combination shows promise in advanced melanoma, despite missing statistical significance for PFS.

Melanie T. Turk, PhD, RN, discusses her study on nationwide challenges program suppliers face in implementing the Medicare Diabetes Prevention Program (MDPP).

Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC, explained Christof Vulsteke, MD, PhD.

Balazs Halmos, MD, of Montefiore Albert Einstein Cancer Center, discussed the potential impact of subcutaneous amivantamab EGFR-mutated NSCLC.

Rebecca Dent, MD, MSc, of the National Cancer Center in Singapore, gives insights on the use of antibody-drug conjugates (ADCs) in early breast cancer treatment.

New KEYNOTE-B96 data add to previous results showing progression-free survival (PFS) and overall survival (OS) improvements vs placebo.

Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without sacrificing quality of life in prostate cancer.

Colorblind energy devices and long-wavelength lasers are safest for darker skin, says Ariella Kauvar, MD, with a thorough patient history and physical exam key to preventing complications.

Adjuvant abemaciclib (Verzenio; Eli Lilly) plus endocrine therapy prolonged survival in high-risk HR-positive, HER2-negative early-stage breast cancer.

Atomic force microscopy successfully identified nanomechanical changes in fibrotic lung tissue.